Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01017952 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,635
- Enrollment target
NCT01017952: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT01017952 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,635 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (112% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01017952, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,635 participants
- Enrollment target
Study Summary
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
Primary Outcome
The annual rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations during the treatment (trt) period (per participant \[par.\] per year) was assessed. An exacerbation of COPD, is defined as the worsening of two or more major symptoms (dyspnea, sputum volume, sputum purulence \[color\]) for at least two consecutive days; or the worsening of any one major symptom together with any one of the minor symptoms (sore throat, cold, fever without other cause, increased coug
Interventions
- DRUG FF/GW642444 Inhalation Powder
- DRUG GW642444 Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,635 participants |
| Start Date | 2009-09-25 |
| Est. Completion | 2011-10-17 |
| Phase | Phase 3 |
What the finished NCT01017952 record still lists
NCT01017952 is an interventional study that assigns participants to a tested intervention. Its 1,635 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (112% higher).
The record links to 0 conditions, and to 2 interventions - of which FF/GW642444 Inhalation Powder is the first listed.
NCT01017952 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01017952 about?
NCT01017952 is a clinical study titled "A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
What is the current status of trial NCT01017952?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,635 participants. The study started on 2009-09-25. Estimated completion is 2011-10-17.
What interventions are being tested in trial NCT01017952?
The interventions under investigation include: FF/GW642444 Inhalation Powder (DRUG), GW642444 Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT01017952?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01017952's enrollment target sits among peer trials
1,635 141st of 2000 higher than 1,860 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- NCT07046260 · 1,650 participants
Prospective Study to Assess a Diagnostic Aid for Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI